The company has initiated the application process, as well as filed a registration statement with the United States Securities and Exchange Commission under the JOBS Act. The company’s shares are currently listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange.

”The US is the largest pharmaceutical market in the world, and now that Oasmia has its first product – Paccal Vet®-CA1, for treatment of cancer in dogs – on the American market, we believe that there is an increased interest in the company among American investors. A final decision for a possible secondary listing will be made later this year”, commented Oasmia’s CEO Julian Aleksov.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).